Literature DB >> 11988495

Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia.

Hooman Allayee1, Kelly L Krass, Päivi Pajukanta, Rita M Cantor, Carla J H van der Kallen, Rebecca Mar, Jerome I Rotter, Tjerk W A de Bruin, Leena Peltonen, Aldons J Lusis.   

Abstract

Familial combined hyperlipidemia (FCH), a common cause of premature coronary artery disease, is genetically complex and poorly understood. Recently, a major locus on chromosome 1q21-23 exhibiting highly significant linkage was identified in Finnish FCH families by use of a parametric analysis. We now report highly significant evidence of linkage (maximum LOD score 3.8, recombination fraction 0) of an important FCH phenotype, elevated apolipoprotein B (apoB) levels, to a distinctly separate locus on chromosome 1p31 in Dutch pedigrees. ApoB is the major protein on very low density and low density lipoproteins, and elevated apoB levels have been used as a surrogate trait for FCH. Additional microsatellite markers in the 1p31 region were genotyped, and evidence of linkage improved (maximum LOD score 4.7) in a multipoint analysis of two markers in the peak region. The leptin receptor gene resides within this locus and is involved in obesity and insulin/glucose homeostasis. However, there was no evidence of an association between leptin receptor and apoB levels, raising the possibility that another gene on this chromosomal region contributes to elevated apoB levels in this Dutch population. This is one of the first loci identified for apoB levels in humans and is the second major locus implicated in the genetic etiology of FCH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988495     DOI: 10.1161/01.res.0000015885.27134.f0

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

1.  Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.

Authors:  Päivi Pajukanta; Hooman Allayee; Kelly L Krass; Ali Kuraishy; Aino Soro; Heidi E Lilja; Rebecca Mar; Marja-Riitta Taskinen; Ilpo Nuotio; Markku Laakso; Jerome I Rotter; Tjerk W A de Bruin; Rita M Cantor; Aldons J Lusis; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

Review 2.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

3.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

Review 4.  Treatment of dyslipidemia in children and adolescents.

Authors:  Kathryn Wood Holmes; Peter Oscar Kwiterovich
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

5.  Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides.

Authors:  Hilary Coon; Yuanpei Xin; Paul N Hopkins; Richard M Cawthon; Sandra J Hasstedt; Steven C Hunt
Journal:  Hum Genet       Date:  2005-06-16       Impact factor: 4.132

6.  Upstream transcription factor 1 influences plasma lipid and metabolic traits in mice.

Authors:  Sulin Wu; Rebecca Mar-Heyming; Eric Z Dugum; Nicholas A Kolaitis; Hongxiu Qi; Päivi Pajukanta; Lawrence W Castellani; Aldons J Lusis; Thomas A Drake
Journal:  Hum Mol Genet       Date:  2009-12-08       Impact factor: 6.150

7.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

8.  A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia.

Authors:  Christopher L Plaisier; Steve Horvath; Adriana Huertas-Vazquez; Ivette Cruz-Bautista; Miguel F Herrera; Teresa Tusie-Luna; Carlos Aguilar-Salinas; Päivi Pajukanta
Journal:  PLoS Genet       Date:  2009-09-11       Impact factor: 5.917

9.  A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia.

Authors:  Adriana Huertas-Vazquez; Christopher L Plaisier; Ruishuang Geng; Blake E Haas; Jenny Lee; Marleen M Greevenbroek; Carla van der Kallen; Tjerk W A de Bruin; Marja-Riitta Taskinen; Kumar N Alagramam; Päivi Pajukanta
Journal:  Hum Genet       Date:  2009-10-09       Impact factor: 4.132

Review 10.  Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.

Authors:  Antonio Gaddi; A F G Cicero; F O Odoo; A A Poli; R Paoletti
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.